KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma

Cytopathology

Volumn 22, Issue 6, 2011, Pages 358-364

  Pang, N K B ^a   Nga, M E ^a   Chin, S Y ^a,b   Ismail, T M ^a   Lim, G L ^a   Soong, R ^b   Salto Tellez, M ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anti EGFR monoclonal antibody therapy; Colorectal adenocarcinoma; Cytological specimens; Direct sequencing; DNA extraction; KRAS and BRAF mutation status; Metastatic

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DNA EXTRACTION; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOPSY, FINE-NEEDLE; COLORECTAL NEOPLASMS; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 81355161673     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2010.00812.x     Document Type: Article

References (29)

1. Italiano A, Hostein I, Soubeyran I et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010;17:1429-34.
2. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
3. Barault L, Veyrie N, Jooste V et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-9.
4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
5. Freeman DJ, Juan T, Reiner M et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008;7:184-90.
6. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
7. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21.
8. Frattini M, Signoroni S, Pilotti S et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 2005;65:11227.
9. Velho S, Moutinho C, Cirnes L et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 2008;8:255.
10. Smouse JH, Cibas ES, Janne PA et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72.
11. Whitehall V, Tran K, Umapathy A et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-52.
12. Troncone G, Malapelle U, Cozzolino I, Palombini L. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010. Epub ahead of print. DOI: 10.1002/dc.21.302.
13. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009;16:196-203.
14. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-9.
15. Messick CA, Sanchez J, Dejulius KL, Church JM, Kalady MF. Genetic and molecular diversity of colon cancer hepatic metastases. Surgery 2009;146:227-31.
16. Locatelli MA, Curigliano G, Fumagalli L et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol (Meeting Abstracts) 2010;28:CRA1008.
17. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.
18. Yen LC, Yeh YS, Chen CW et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009;15:4508-13.
19. Klebig F, Fischer C, Petri S et al. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer. Diagn Mol Pathol 2007;16:91-5.
20. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
21. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-25.
22. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
23. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
24. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
25. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
26. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
27. Tol J, Dijkstra JR, Klomp M et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009.
28. van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
29. Quek TPL, Yan B, Yong WP, Salto-Tellez M. Targeted therapeutics-oriented tumor classification: a paradigm shift. Personalized Medicine 2009;6:465-8.